|
|
Article: Alseres Pharmaceuticals, Inc. to Address a Congressional Briefing on Paralysis Research and the Spinal Cord Injury Community at 'Working 2 Walk' in Washington, DC, April 13-15, 2008.
- Article from:
- PR Newswire
- Article date:
- April 9, 2008
|
Copyright informationCOPYRIGHT 2008 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Dr. Mark Hurtt, Chief Medical Officer, to present interim results of the Cethrin(R) Phase I/IIa Clinical Trial in Acute Spinal Cord Injury
HOPKINTON, Mass., April 9, 2008 /PRNewswire-FirstCall/ -- Alseres Pharmaceuticals, Inc. announced that on April 15, 2008, Dr. Mark Hurtt, Chief Medical Officer, will discuss the CETHRIN development program as a member of an expert panel on Spinal Cord Injury Research during a congressional briefing on Capitol Hill focused on "Rapid Advancements in Paralysis Research." In addition, Dr. Hurtt will present interim results of the CETHRIN Phase I/IIa clinical trial in acute spinal cord injury during a plenary session on April 13, 2008 at ...
Related newspaper, magazine, and journal articles:
|